Creative Life Science Co Ltd
TTPEX:783781.50
TWD
+0.50
(+0.62%)
ISIN
TW0007837007
Return %
Stock
S&P 500
1Y
-28.51
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yue Ting Cai
- Full Time Employees
- 365
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- New Taipei City Taiwan
- Website
- cmp-micro.com
- Similar Companies
- Business
- Creative Life Science Co., Ltd. is a Taiwan-based biotechnology and healthcare company engaged in the research, development, manufacturing, and commercialization of biomedical products, in vitro diagnostics, and functional health supplements. Founded in Taiwan and headquartered in Taipei, the company operates across specialized life science sectors, serving medical institutions, diagnostic laboratories, healthcare brand owners, and consumer wellness markets across Taiwan and the broader Asia-Pacific region. The company organizes its core business into several comprehensive product and service segments, comprising in vitro diagnostic (IVD) reagents, rapid test cassettes, and point-of-care testing systems for clinical diagnostics and infectious disease screening; specialized probiotic formulations, botanical wellness extracts, immune-support supplements, and functional nutritional health products; contract development and manufacturing organization (CDMO), original equipment manufacturing (OEM), and original design manufacturing (ODM) services for biopharmaceutical, cosmetic, and nutritional health brands; and life science laboratory supplies, including molecular biology test reagents, cell culture media, and biochemical analytical consumables. In recent corporate developments, Creative Life Science Co., Ltd. has advanced its capital and market presence through its public listing on the Emerging Stock Board of the Taipei Exchange under ticker TPEX:7837. Over the past two years, the company has upgraded and expanded its certified production infrastructure to scale its CDMO and diagnostic manufacturing capacity, established strategic co-development and distribution agreements with healthcare partners and regional research centers to introduce next-generation preventive diagnostics, and launched specialized lines of clinical-grade functional nutritional formulas. In addition, the company continues to broaden its international regulatory compliance and product registrations to support the geographic expansion of its diagnostic and wellness offerings into Southeast Asian and overseas markets.